Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics
ABUS Price/Volume Stats
| Current price | $2.71 | 52-week high | $3.29 |
| Prev. close | $2.68 | 52-week low | $1.69 |
| Day low | $2.70 | Volume | 683,600 |
| Day high | $2.85 | Avg. volume | 1,217,515 |
| 50-day MA | $2.75 | Dividend yield | N/A |
| 200-day MA | $2.28 | Market Cap | 486.42M |
ABUS Stock Price Chart Interactive Chart >
Arbutus Biopharma Corporation (ABUS) Company Bio
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.
Latest ABUS News From Around the Web
Below are the latest news stories about ARBUTUS BIOPHARMA CORP that investors may wish to consider to help them evaluate ABUS as an investment opportunity.
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLDInitial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well-tolerated in both trials. OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at Th |
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatiti |
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call TranscriptArbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript November 7, 2023 Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call. [Operator Instructions] Please be advised that […] |
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This WeekCelebrations may be in order for Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders, with the analysts... |
Arbutus to Present at Jefferies London Healthcare ConferenceWARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference: Jefferies London Healthcare Conference: Formal presentation on Wednesday, |
ABUS Price Returns
| 1-mo | -13.14% |
| 3-mo | 14.83% |
| 6-mo | 46.49% |
| 1-year | 4.23% |
| 3-year | -3.21% |
| 5-year | 9.72% |
| YTD | 8.40% |
| 2023 | 7.30% |
| 2022 | -40.10% |
| 2021 | 9.58% |
| 2020 | 27.70% |
| 2019 | -27.42% |
Continue Researching ABUS
Want to do more research on Arbutus Biopharma Corp's stock and its price? Try the links below:Arbutus Biopharma Corp (ABUS) Stock Price | Nasdaq
Arbutus Biopharma Corp (ABUS) Stock Quote, History and News - Yahoo Finance
Arbutus Biopharma Corp (ABUS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...